Short Communication: Nucleoside Reverse Transcriptase Inhibitors with Reduced Predicted Activity Do Not Impair Second-Line Therapy with Lopinavir/Ritonavir or Darunavir/Ritonavir
Journal article published in 2018 by
Christian Julian Villabona-Arenas,
Sabrina Eymard-Duvernay,
Avelin Aghokeng,
Emilande Guichet,
Coumba Toure-Kane,
Guillaume Bado,
Sinata Koulla-Shiro,
Eric Delaporte 
,
Laura Ciaffi,
Martine Peeters
,
Laura Ciaffi,
Martine Peeters
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 